Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 12/20 | 0.61 |
| ▸ | TXK | P42681 | 10/20 | 0.61 |
| ▸ | BTK | Q06187 | 10/20 | 0.61 |
| ▸ | JAK3 | P52333 | 10/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20161432 | 0.92 | ITK (0.62) | ITKTXKBTKJAK3 | |
| SCHEMBL14460569 | 0.91 | ITK (0.70) | ITKTXKBTKJAK3 | |
| SCHEMBL30291400 | 0.91 | ITK (0.70) | ITKTXKBTKJAK3 | |
| SCHEMBL14460588 | 0.90 | ITK (0.60) | ITKTXKBTKJAK3 | |
| SCHEMBL20162006 | 0.90 | JAK3 (0.62) | ITKTXKBTKJAK3 | |
| SCHEMBL20161228 | 0.88 | TXK (0.61) | ITKTXKBTKJAK3 | |
| SCHEMBL29932924 | 0.88 | TXK (0.61) | ITKTXKBTKJAK3 | |
| SCHEMBL14461105 | 0.87 | JAK3 (0.63) | ITKTXKBTKJAK3 | |
| SCHEMBL24467210 | 0.84 | JAK3 (0.59) | ITKTXKBTKJAK3 | |
| SCHEMBL20161618 | 0.84 | JAK3 (0.61) | ITKTXKBTKJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226196-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF INTERLEUKIN-2-INDUCIBLE T-CELL KINASE AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230226196-A1 | COMPOUNDS FOR TARGETED DEGRADATION OF INTERLEUKIN-2-INDUCIBLE T-CELL KINASE AND METHODS OF USE | ITK, IKZF2, PBK | ITK 1/4885TXK 47/4885BTK 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.